|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2022
Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M.-A.; Im, S.-A.; Ahn, J.-H.; Gion, M.; Baron-Hay, S.; Boileau, J.-F.; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V. und O'Shaughnessy, J.
(2022):
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
In: New England Journal of Medicine, Bd. 386, Nr. 6: S. 556-567
2021
Harbeck, N.; Rastogi, P.; Martin, M.; Tolaney, S. M.; Shao, Z. M.; Fasching, P. A.; Huang, C. S.; Jaliffe, G. G.; Tryakin, A.; Goetz, M. P.; Rugo, H. S.; Senkus, E.; Testa, L.; Andersson, M.; Tamura, K.; Del Mastro, L.; Steger, G. G.; Kreipe, H.; Hegg, R.; Sohn, J.; Guarneri, V.; Cortes, J.; Hamilton, E.; Andre, V.; Wei, R.; Barriga, S.; Sherwood, S.; Forrester, T.; Munoz, M.; Shahir, A.; San Antonio, B.; Nabinger, S. C.; Toi, M.; Johnston, S. R. D. und O'Shaughnessy, J.
(2021):
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
In: Annals of Oncology, Bd. 32, Nr. 12: S. 1571-1581
2018
Yardley, D. A.; Coleman, R.; Conte, P.; Cortes, J.; Brufsky, A.; Shtivelband, M.; Young, R.; Bengala, C.; Ali, H.; Eakel, J.; Schneeweiss, A.; de la Cruz-Merino, L.; Wilks, S.; O'Shaughnessy, J.; Gluck, S.; Li, H.; Miller, J.; Barton, D. und Harbeck, N.
(2018):
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
In: Annals of Oncology, Bd. 29, Nr. 8: S. 1763-1770
2017
Mamounas, E. P.; Goldstein, L. J.; Penault-Llorca, F.; Roché, H.; Gluz, O.; Harbeck, N.; Nitz, U.; O'Shaughnessy, J. und Albain, K. S.
(2017):
Chemotherapy (CT) decision in node-positive (N plus ), ER plus , early breast cancer (EBC) after new ASCO Guideline - evidence for the 21-gene Recurrence Score (RS) assay.
In: Breast, Bd. 32:
S98-S98
Mamounas, E.; Goldstein, L.; Penault-Llorca, F.; Roche, H.; Gluz, O.; Harbeck, N.; Nitz, U.; O'Shaughnessy, J. und Albain, K.
(2017):
Chemotherapy (CT) decision in patients (pts) with node-positive (N plus ), ER plus , early breast cancer (EBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay.
In: Cancer Research, Bd. 77